Promising molecular mechanisms responsible for gemcitabine resistance in cancer

Gemcitabine is the first-line treatment for pancreatic ductual adenocarcinoma (PDAC) as well as acts against a wide range of other solid tumors. Patients usually have a good initial response to gemcitabine-based chemotherapy but would eventually develop resistance. To improve survival and prognosis of cancer patients, better understanding of the mechanisms responsible for gemcitabine resistance and discovery of new therapeutic strategies are in great need. Amounting evidence indicate that the developmental pathways, such as Hedgehog (Hh), Wnt and Notch, become reactivated in gemcitabine-resistant cancer cells. Thus, the strategies for targeting these pathways may sensitize cancer cells to gemcitabine treatment. In this review, we will summarize recent development in this area of research and discuss strategies to overcome gemcitabine resistance. Given the cross-talk between these three developmental signaling pathways, designing clinical trials using a cocktail of inhibitory agents targeting all these pathways may be more effective. Ultimately, our hope is that targeting these developmental pathways may be an effective way to improve the gemcitabine treatment outcome in cancer patients.

• Publication year

  2015

• Venue

  Genes and Diseases

• Publication date

  2015-07-30

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.gendis.2015.07.003PMID 30258872PMCID 6150077
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maslinic acid potentiates the antitumor activities of gemcitabine in vitro and in vivo by inhibiting NF-κB-mediated survival signaling pathways in human gallbladder cancer cells.

  2015cited by this paper
• Side population cells of pancreatic cancer show characteristics of cancer stem cells responsible for resistance and metastasis

  2015cited by this paper
• HES 1 is essential for chemoresistance induced by stellate cells and is associated with poor prognosis in pancreatic cancer.

  2015influential reference
• Intracellular annexin A2 regulates NF-κB signaling by binding to the p50 subunit: implications for gemcitabine resistance in pancreatic cancer

  2015cited by this paper
• The MUC1 oncomucin regulates pancreatic cancer cell biological properties and chemoresistance. Implication of p42-44 MAPK, Akt, Bcl-2 and MMP13 pathways.

  2015cited by this paper
• ABC transporters in CSCs membranes as a novel target for treating tumor relapse

  2014cited by this paper
• Gemcitabine resistance is associated with epithelial-mesenchymal transition and induction of HIF-1α in pancreatic cancer cells.

  2014cited by this paper
• Perifosine inhibits S6K1–Gli1 signaling and enhances gemcitabine-induced anti-pancreatic cancer efficiency

  2014cited by this paper
• Chloroquine Targets Pancreatic Cancer Stem Cells via Inhibition of CXCR4 and Hedgehog Signaling

  2014cited by this paper
• [Down-regulation of Notch1 by small interfering RNA enhances chemosensitivity to gemcitabine in pancreatic cancer cells through activating apoptosis activity].

  2014cited by this paper
• Gemcitabine resistance in breast cancer cells regulated by PI3K/AKT-mediated cellular proliferation exerts negative feedback via the MEK/MAPK and mTOR pathways

  2014cited by this paper
• Alteration of the intrinsic apoptosis pathway is involved in Notch-induced chemoresistance to gemcitabine in pancreatic cancer.

  2014cited by this paper
• The heparan sulfate mimetic PG545 interferes with Wnt/β-catenin signaling and significantly suppresses pancreatic tumorigenesis alone and in combination with gemcitabine

  2014cited by this paper
• Combining Hedgehog Signaling Inhibition with Focal Irradiation on Reduction of Pancreatic Cancer Metastasis

  2013cited by this paper
• Notch pathway activation is associated with pancreatic cancer treatment failure.

  2013cited by this paper
• Array analysis for potential biomarker of gemcitabine identification in non-small cell lung cancer cell lines.

  2013cited by this paper
• MAP3K10 promotes the proliferation and decreases the sensitivity of pancreatic cancer cells to gemcitabine by upregulating Gli-1 and Gli-2.

  2013cited by this paper
• Arsenic trioxide inhibits viability of pancreatic cancer stem cells in culture and in a xenograft model via binding to SHH-Gli

  2013cited by this paper
• Human equilibrative nucleoside transporter 1 and Notch3 can predict gemcitabine effects in patients with unresectable pancreatic cancer

  2013cited by this paper
• Lithium Inhibits Tumorigenic Potential of PDA Cells through Targeting Hedgehog-GLI Signaling Pathway

  2013influential reference
• ABCB2 (TAP1) as the downstream target of SHH signaling enhances pancreatic ductal adenocarcinoma drug resistance.

  2013cited by this paper
• WNT5A-NFAT signaling mediates resistance to apoptosis in pancreatic cancer.

  2013cited by this paper
• The EMT activator ZEB1 promotes tumor growth and determines differential response to chemotherapy in mantle cell lymphoma

  2013cited by this paper
• The complex world of WNT receptor signalling

  2012cited by this paper
• The Gamma Secretase Inhibitor MRK-003 Attenuates Pancreatic Cancer Growth in Preclinical Models

  2012cited by this paper
• Hedgehog signaling is a novel therapeutic target in tamoxifen-resistant breast cancer aberrantly activated by PI3K/AKT pathway.

  2012cited by this paper
• Sonic hedgehog maintains survival and growth of chronic myeloid leukemia progenitor cells through β-catenin signaling.

  2012cited by this paper
• Pancreatic cancer cells surviving gemcitabine treatment express markers of stem cell differentiation and epithelial-mesenchymal transition.

  2012cited by this paper
• Gamma secretase inhibition promotes hypoxic necrosis in mouse pancreatic ductal adenocarcinoma

  2012cited by this paper
• Differentiation pathways in carcinogenesis and in chemo- and radioresistance.

  2012cited by this paper
• GLI1 modulates EMT in pancreatic cancer--letter.

  2012cited by this paper
• Anti-DLL4 Has Broad Spectrum Activity in Pancreatic Cancer Dependent on Targeting DLL4-Notch Signaling in Both Tumor and Vasculature Cells

  2012cited by this paper
• Sonic Hedgehog Pathway Is Essential for Maintenance of Cancer Stem-Like Cells in Human Gastric Cancer

  2011cited by this paper
• Cyclopamine induces eosinophilic differentiation and upregulates CD44 expression in myeloid leukemia cells.

  2011cited by this paper
• Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways

  2011cited by this paper
• Expression and promoter methylation analysis of ATP-binding cassette genes in pancreatic cancer.

  2011cited by this paper
• Altered differentiation and paracrine stimulation of mammary epithelial cell proliferation by conditionally activated Smoothened.

  2011cited by this paper
• Jagged2 controls the generation of motor neuron and oligodendrocyte progenitors in the ventral spinal cord

  2011cited by this paper
• Notch signaling activated by replication stress-induced expression of midkine drives epithelial-mesenchymal transition and chemoresistance in pancreatic cancer.

  2011cited by this paper
• Sulforaphane increases drug-mediated cytotoxicity toward cancer stem-like cells of pancreas and prostate.

  2011cited by this paper
• Phase I Trial of Hedgehog Pathway Inhibitor Vismodegib (GDC-0449) in Patients with Refractory, Locally Advanced or Metastatic Solid Tumors

  2011cited by this paper
• Jagged1 Expression Regulated by Notch3 and Wnt/β-catenin Signaling Pathways in Ovarian Cancer

  2010cited by this paper
• Masitinib Combined with Standard Gemcitabine Chemotherapy: In Vitro and In Vivo Studies in Human Pancreatic Tumour Cell Lines and Ectopic Mouse Model

  2010cited by this paper
• Modulation of the Ribonucleotide Reductase-Antimetabolite Drug Interaction in Cancer Cell Lines

  2010cited by this paper
• Targeting Notch signaling pathway to overcome drug resistance for cancer therapy.

  2010cited by this paper
• Inhibition of Notch3 enhances sensitivity to gemcitabine in pancreatic cancer through an inactivation of PI3K/Akt-dependent pathway

  2010cited by this paper
• The Notch Target Hes1 Directly Modulates Gli1 Expression and Hedgehog Signaling: A Potential Mechanism of Therapeutic Resistance

  2010cited by this paper
• gamma-Secretase inhibitors abrogate oxaliplatin-induced activation of the Notch-1 signaling pathway in colon cancer cells resulting in enhanced chemosensitivity.

  2009cited by this paper
• The role of HuR in gemcitabine efficacy in pancreatic cancer: HuR Up-regulates the expression of the gemcitabine metabolizing enzyme deoxycytidine kinase.

  2009cited by this paper
• The Hedgehog signaling pathway plays an essential role in maintaining the CD44+CD24-/low subpopulation and the side population of breast cancer cells.

  2009cited by this paper
• Targeting AKT with the proapoptotic peptide, TAT‐CTMP: A novel strategy for the treatment of human pancreatic adenocarcinoma

  2009cited by this paper
• Acquisition of epithelial-mesenchymal transition phenotype of gemcitabine-resistant pancreatic cancer cells is linked with activation of the notch signaling pathway.

  2009cited by this paper
• Hedgehog signalling: emerging evidence for non-canonical pathways.

  2009cited by this paper
• Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells

  2008cited by this paper
• Primers on Molecular Pathways – Notch

  2008cited by this paper
• Carboplatin plus gemcitabine repeating doublet therapy in recurrent breast cancer.

  2008cited by this paper
• Gemcitabine Plus Carboplatin Compared With Carboplatin in Patients With Platinum-Sensitive Recurrent Ovarian Cancer: An Intergroup Trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG

  2008cited by this paper
• Cyclopamine‐Mediated Hedgehog Pathway Inhibition Depletes Stem‐Like Cancer Cells in Glioblastoma

  2007cited by this paper
• Cell and molecular biology of Notch.

  2007cited by this paper
• Hedgehog signaling and Bmi-1 regulate self-renewal of normal and malignant human mammary stem cells.

  2006cited by this paper
• Cellular pharmacology of gemcitabine.

  2006cited by this paper
• Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: an intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG.

  2006cited by this paper
• Suppressing Wnt Signaling by the Hedgehog Pathway through sFRP-1*

  2006cited by this paper
• EXPRESSION OF UBIQUITIN-SPECIFIC PROTEASE 14 IN HUMAN PANCREATIC CANCER CELL LINES AND CANCER TISSUES

  2005cited by this paper
• The Wnt signaling pathway in development and disease.

  2004cited by this paper
• The Absence of Human Equilibrative Nucleoside Transporter 1 Is Associated with Reduced Survival in Patients With Gemcitabine-Treated Pancreas Adenocarcinoma

  2004cited by this paper
• Role of NF-kappaB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death.

  2003cited by this paper
• A second canon. Functions and mechanisms of beta-catenin-independent Wnt signaling.

  2003cited by this paper
• Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell death

  2003cited by this paper
• A Second Canon

  2003cited by this paper
• Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large, randomized, multinational, multicenter, phase III study.

  2000cited by this paper
• Equilibrative-sensitive nucleoside transporter and its role in gemcitabine sensitivity.

  2000cited by this paper
• Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer.

  2000cited by this paper
• Overexpression of transfected human ribonucleotide reductase M2 subunit in human cancer cells enhances their invasive potential

  1998cited by this paper
• A binding site for Gli proteins is essential for HNF-3beta floor plate enhancer activity in transgenics and can respond to Shh in vitro.

  1997cited by this paper
• Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial.

  1997cited by this paper
• Inhibition of ribonucleotide reductase by 2'-substituted deoxycytidine analogs: possible application in AIDS treatment.

  1994cited by this paper
• Cellular elimination of 2',2'-difluorodeoxycytidine 5'-triphosphate: a mechanism of self-potentiation.

  1992cited by this paper
• Action of 2',2'-difluorodeoxycytidine on DNA synthesis.

  1991cited by this paper
• Evaluation of the antitumor activity of gemcitabine (2',2'-difluoro-2'-deoxycytidine).

  1990cited by this paper
• The GLI gene encodes a nuclear protein which binds specific sequences in the human genome

  1990cited by this paper
• Modulatory activity of 2',2'-difluorodeoxycytidine on the phosphorylation and cytotoxicity of arabinosyl nucleosides.

  1990cited by this paper

• Ataxia-telangiectasia mutated kinase inhibition overcomes gemcitabine resistance in intrahepatic cholangiocarcinoma via DNA ligase I-dependent repair vulnerability.

  2026cites this paper
• Efficacy and Safety of Disitamab Vedotin Combined with Gemcitabine as Neoadjuvant Therapy in Muscle-invasive Bladder Cancer: An Open-label, Multicenter, Single-arm, Phase 2 Trial.

  2025cites this paper
• Extracellular Vesicle‐Mediated Regulation of H3C14 Contributes to Gemcitabine Resistance in Bladder Cancer

  2025cites this paper
• Targeting FUT1-mediated EGFR fucosylation and COX-2 reverses gemcitabine resistance by activating immunogenic cell death in hepatocellular carcinoma.

  2025cites this paper
• Role of Ubiquitin-regulated EMT in Cancer Metastasis and Chemoresistance

  2025cites this paper
• Checkpoint-Dependent Sensitivities to Nucleoside Analogues Uncover Specific Patterns of Genomic Instability

  2025cites this paper
• KRAS G12C inhibition enhances efficacy to conventional chemotherapy in KRAS-mutant NSCLC

  2025cites this paper
• Sustained and localized delivery of gemcitabine using chitosan-PVA-TPP polymeric implant enhances antitumor efficacy and delays surgical relapse in pancreatic cancer.

  2025cites this paper
• CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells

  2025cites this paper
• A new era in cancer therapy: targeting the Proteasome-Bcl-2 axis

  2025cites this paper
• The pro-apoptotic peptide PEP-010 triggers apoptosis in pancreatic tumor models in monotherapy and in combination with gemcitabine independently of the KRAS status.

  2025cites this paper
• ABCG2 protein expression in tumors of patients with non-resectable pancreatic cancer treated with gemcitabine and nab-paclitaxel

  2025cites this paper
• Apoptosis regulators of the Bcl‐2 family play a key role in chemoresistance of cholangiocarcinoma organoids

  2025cites this paper
• DSG2 attenuates gemcitabine efficacy through PTX3 in lung adenocarcinoma.

  2025cites this paper
• miR‐135b‐5p/PDE3B Axis Regulates Gemcitabine Resistance in Pancreatic Cancer Through Epithelial‐Mesenchymal Transition

  2025cites this paper
• Circular RNAs: driving forces behind chemoresistance and immune evasion in bladder cancer

  2025cites this paper
• Extracellular Vesicle‐Packaged Linc‐ZNF25‐1 from Pancreatic Cancer Cell Promotes Pancreatic Stellate Cell Uptake of Asparagine to Advance Chemoresistance

  2025cites this paper
• Unlocking the Microbial Symphony: The Interplay of Human Microbiota in Cancer Immunotherapy Response

  2025cites this paper
• Harnessing the Efficiency of Twin Boron Nitride and Graphene Monolayers for Anticancer Drug Delivery: Insights from DFT

  2025cites this paper
• High-density lipoprotein-based nanoplatform reprograms tumor microenvironment and enhances chemotherapy against pancreatic ductal adenocarcinoma.

  2025cites this paper
• Curcumin-Loaded Maltodextrin-Based Proniosomes Potentially Effective against Gemcitabine-Resistant Cholangiocarcinoma

  2025cites this paper
• F41, a Novel Fungal Indole-Diterpenoid, Overcomes Gemcitabine Resistance in Pancreatic Cancer by Inducing ER Stress

  2025cites this paper
• Solid-Lipid Nanoparticle (SLN) Based Approaches for Enhancing the Therapeutic Efficacy of Anticancer Drugs in Targeting Gastrointestinal Malignancies

  2025cites this paper
• Glycogen synthase kinase 3β: the nexus of chemoresistance, invasive capacity, and cancer stemness in pancreatic cancer

  2024cites this paper
• Aurora B facilitates cholangiocarcinoma progression by stabilizing c‐Myc

  2024cites this paper
• Prediction of anticancer drug resistance using a 3D microfluidic bladder cancer model combined with convolutional neural network-based image analysis

  2024cites this paper
• Cancer Mutations Converge on a Collection of Protein Assemblies to Predict Resistance to Replication Stress

  2024cites this paper
• Pyrvinium Pamoate Alone and With Gemcitabine Exhibits Anti‐Pancreatic Cancer Activity in 2D and 3D Cell Culture Models

  2024cites this paper
• Chemoresistance-Motility Signature of Molecular Evolution to Chemotherapy in Non-Muscle-Invasive Bladder Cancer and Its Clinical Implications.

  2024cites this paper
• Application of cisplatin and other platinum-containing drugs in cancer therapy: Comprehensive review

  2024cites this paper
• Targeting ketone body metabolism in mitigating gemcitabine resistance

  2024cites this paper
• Extracellular Signal-Regulated Kinase Inhibitor SCH772984 Augments the Anti-Cancer Effects of Gemcitabine in Nanoparticle Form in Pancreatic Cancer Models

  2024cites this paper
• Synergistic Inhibition of Pancreatic Cancer Cell Growth and Migration by Gemcitabine and Withaferin A

  2024cites this paper
• Aqueous Extracts of Ocimum gratissimum Sensitize Hepatocellular Carcinoma Cells to Cisplatin through BRCA1 Inhibition

  2024cites this paper
• Somatic Mutation Profile as a Predictor of Treatment Response and Survival in Unresectable Pancreatic Ductal Adenocarcinoma Treated with FOLFIRINOX and Gemcitabine Nab-Paclitaxel

  2024cites this paper
• Atypical phosphatase DUSP11 inhibition promotes nc886 expression and potentiates gemcitabine-mediated cell death through NF-kB modulation

  2024cites this paper
• YAP‐LAMB3 axis dictates cellular resistance of pancreatic ductal adenocarcinoma cells to gemcitabine

  2024cites this paper
• Secretory Trefoil Factor 1 (TFF1) promotes gemcitabine resistance through chemokine receptor CXCR4 in Pancreatic Ductal Adenocarcinoma.

  2024cites this paper
• A fluorescent gemcitabine prodrug that follows a nucleoside transporter-independent internalization and bears enhanced therapeutic efficacy with respect to gemcitabine.

  2024cites this paper
• LncRNA DYNLRB2-AS1 promotes gemcitabine resistance of nasopharyngeal carcinoma by inhibiting the ubiquitination degradation of DHX9 protein.

  2024cites this paper
• Targeting Neoantigens in Pancreatic Ductal Adenocarcinoma

  2024cites this paper
• Chitosan-PLGA mucoadhesive nanoparticles for gemcitabine repurposing for glioblastoma therapy.

  2024cites this paper
• Repurposing gemcitabine for glioblastoma treatment: the role of drug-conjugates and nanoparticles as drug delivery systems

  2024cites this paper
• Microbiome and cancer: from mechanistic implications in disease progression and treatment to development of novel antitumoral strategies

  2024cites this paper
• Thermosensitive polymer prodrug nanoparticles prepared by an all-aqueous nanoprecipitation process and application to combination therapy.

  2024cites this paper
• Deciphering the role of Enterococcus faecium cytidine deaminase in gemcitabine resistance of gallbladder cancer

  2024cites this paper
• Synergistic antitumor activity between HER2 antibody-drug conjugate and chemotherapy for treating advanced colorectal cancer

  2024cites this paper
• Deoxycytidine kinase inactivation enhances gemcitabine resistance and sensitizes mitochondrial metabolism interference in pancreatic cancer

  2024cites this paper
• Enhancing chemosensitivity of PANC1 pancreatic cancer cells to gemcitabine using ANGTPL4, Notch1 and NF-κβ1 siRNAs

  2024cites this paper
• Dysregulation of the circ_0087502/miR-1179/TGFBR2 pathway supports gemcitabine resistance in pancreatic cancer

  2023cites this paper
• Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance

  2023cites this paper
• MYC/glutamine dependency is a therapeutic vulnerability in pancreatic cancer with deoxycytidine kinase inactivation-induced gemcitabine resistance.

  2023cites this paper
• Kaempferol with Verapamil impeded panoramic chemoevasion pathways in breast cancer through ROS overproduction and disruption of lysosomal biogenesis.

  2023cites this paper
• Atractylodin and β-eudesmol from Atractylodes lancea (Thunb.) DC. Inhibit Cholangiocarcinoma Cell Proliferation by Downregulating the Notch Signaling Pathway

  2023cites this paper
• Co-delivery of gemcitabine and Triapine by calcium carbonate nanoparticles against chemoresistant pancreatic cancer.

  2023cites this paper
• ELF3 promotes gemcitabine resistance through PKMYT1/CDK1 signaling pathway in gallbladder cancer

  2023cites this paper
• circACTR2 attenuates gemcitabine chemoresiatance in pancreatic cancer through PTEN mediated PI3K/AKT signaling pathway

  2023cites this paper
• Characterization and treatment of gemcitabine‐ and cisplatin‐resistant bladder cancer cells with a pan‐RAS inhibitor

  2023cites this paper
• Chemomodulatory Effect of the Marine-Derived Metabolite “Terrein” on the Anticancer Properties of Gemcitabine in Colorectal Cancer Cells

  2023cites this paper
• Petite Integration Factor 1 knockdown enhances gemcitabine sensitivity in pancreatic cancer cells via increasing DNA damage

  2023cites this paper
• Phosphorylation of Bcl‐2 by JNK confers gemcitabine resistance in lung cancer cells by reducing autophagy‐mediated cell death

  2023cites this paper
• Novel Chlorin e6-Curcumin Derivatives as a Potential Photosensitizer: Synthesis, Characterization, and Anticancer Activity

  2023cites this paper
• Interplay between MAP kinases and tumor microenvironment: Opportunity for immunotherapy in pancreatic cancer.

  2023cites this paper
• Shielding and nurturing: Fibronectin as a modulator of cancer drug resistance

  2023cites this paper
• Gemcitabine and rapamycin-loaded mixed polymeric thermogel for metastatic pancreatic cancer therapy.

  2023cites this paper
• The impact of microRNAs on the resistance of breast cancer subtypes to chemotherapy.

  2023cites this paper
• Nucleoside-based anticancer drugs: mechanism of action and drug resistance.

  2023cites this paper
• Profiling single cancer cell metabolism via high-content SRS imaging with chemical sparsity

  2023cites this paper
• Calycosin inhibits gemcitabine-resistant lung cancer cells proliferation through modulation of the LDOC1/GNL3L/NFκB

  2023cites this paper
• Gemcitabine therapeutically disrupts essential SIRT1-mediated p53 repression in atypical teratoid/rhabdoid tumors

  2023cites this paper
• PAK4 inhibition significantly potentiates Gemcitabine activity in PDAC cells via inhibition of Wnt/β-catenin, p-ERK/MAPK and p-AKT/PI3K pathways

  2023cites this paper
• The emerging role of the gut microbiome in cancer cell plasticity and therapeutic resistance

  2023cites this paper
• SLC38A5 Modulates Ferroptosis to Overcome Gemcitabine Resistance in Pancreatic Cancer

  2023cites this paper
• AUM302, a novel triple kinase PIM/PI3K/mTOR inhibitor, is a potent in vitro pancreatic cancer growth inhibitor

  2023cites this paper
• Nanomedicine Combats Drug Resistance in Lung Cancer

  2023cites this paper
• Large-Scale Machine Learning Analysis Reveals DNA Methylation and Gene Expression Response Signatures for Gemcitabine-Treated Pancreatic Cancer

  2023cites this paper
• Responsive Nanomaterial Delivery Systems for Pancreatic Cancer Management

  2023cites this paper
• Amurensin G Sensitized Cholangiocarcinoma to the Anti-Cancer Effect of Gemcitabine via the Downregulation of Cancer Stem-like Properties

  2023cites this paper
• Transcriptomic and functional analysis of ANGPTL4 overexpression in pancreatic cancer nominates targets that reverse chemoresistance

  2023cites this paper
• Efficacy of HMJ-38, a new quinazolinone analogue, against the gemcitabine-resistant MIA-PaCa-2 pancreatic cancer cells

  2023cites this paper
• The anthelmintic drug niclosamide induces GSK-β-mediated β-catenin degradation to potentiate gemcitabine activity, reduce immune evasion ability and suppress pancreatic cancer progression

  2022cites this paper
• The Senescence-Related Signature Predicts Prognosis and Characterization of Tumor Microenvironment Infiltration in Pancreatic Cancer

  2022cites this paper
• Stepwise molecular mechanisms responsible for chemoresistance in bladder cancer cells

  2022cites this paper
• Role of microbiota and microbiota‐derived short‐chain fatty acids in PDAC

  2022influential citation
• Berberine Overcomes Gemcitabine-Associated Chemoresistance through Regulation of Rap1/PI3K-Akt Signaling in Pancreatic Ductal Adenocarcinoma

  2022cites this paper
• Nanoparticles design considerations to co-deliver nucleic acids and anti-cancer drugs for chemoresistance reversal

  2022cites this paper
• Ameliorating the antitumor activity of gemcitabine against breast tumor using αvβ3 integrin-targeting lipid nanoparticles

  2022cites this paper
• Insight into the interplay between mitochondria-regulated cell death and energetic metabolism in osteosarcoma

  2022cites this paper
• Effects of microbiota on anticancer drugs: Current knowledge and potential applications

  2022cites this paper
• miRNAs are now starring in “No Time to Die: Overcoming the chemoresistance in cancer”

  2022cites this paper
• Progesterone receptor expression contributes to gemcitabine resistance at higher ECM stiffness in breast cancer cell lines

  2022cites this paper
• LINC00665: An Emerging Biomarker for Cancer Diagnostics and Therapeutics

  2022cites this paper
• Mechanisms of resistance to chemotherapy in non-small cell lung cancer

  2021cites this paper
• Zinc-related Treatments Combined with Chloroquine and Gemcitabine for Treating Pancreatic Cancer

  2021cites this paper
• Ellagic Acid Resensitizes Gemcitabine-Resistant Bladder Cancer Cells by Inhibiting Epithelial-Mesenchymal Transition and Gemcitabine Transporters

  2021influential citation
• Improving Gemcitabine Sensitivity in Pancreatic Cancer Cells by Restoring miRNA-217 Levels

  2021influential citation
• The diverse roles of circular RNAs in pancreatic cancer.

  2021cites this paper
• Intracellular KRAS-specific antibody enhances the anti-tumor efficacy of gemcitabine in pancreatic cancer by inducing endosomal escape.

  2021cites this paper
• A Pharmacological Analysis of the Activity and Failure of the Medical Treatment of High-Grade Osteosarcoma

  2021cites this paper
• PVT1 Knockdown Inhibits Autophagy and Improves Gemcitabine Sensitivity by Regulating the MiR-143/HIF-1α/VMP1 Axis in Pancreatic Cancer

  2021cites this paper